Drug firm Vivimed Labs today said it has inked pacts to acquire Hungary-based contract development and manufacturing firm Soneas for an undisclosed amount.
Vivimed Labs Spain S.L, the parent of Uquifa S.A has signed definitive agreements to facilitate the acquisition of Soneas, Vivimed Labs said in a BSE filing.
"The acquisition broadens Uquifa's market offering in the contract development and manufacturing organisation (CDMO) space by enhancing its ability to now undertake preclinical, phase I, II and III NCE project development," Vivimed Labs said.
Shares of Vivimed Labs today closed at Rs 67.80 per scrip on BSE, up 2.73 per cent from its previous close. PTI AKT.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app